SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC

Author's Avatar
May 01, 2018
Article's Main Image

QIDP provides five additional years of market exclusivity, and Fast Track expedites the regulatory path

Enrollment completed in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018

Initiation of Phase 3 registration program in VVC planned for the fourth quarter of 2018, with potential NDA filing in 2020

PR Newswire